Press Releases
Bexion Pharmaceuticals, Inc. Appoints Dr. Catherine Pearce, DHSc, MBA, to Board of Directors
COVINGTON, Ky., Oct. 10, 2023 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Dr. Catherine Pearce, DHSc, MBA, to the Company's Board of Directors, effective October 1, 2023. Dr. Catherine Pearce, DHSc, MBA Dr. Pearce is a seasoned [...]
Bexion Pharmaceuticals, Inc. to Participate in the 2023 Cantor Global Healthcare Conference
COVINGTON, Ky., Sept. 25, 2023 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will participate in the 2023 Cantor Global Healthcare Conference. The conference will be held in New York, NY, from September 26-28, 2023. Scott Shively, CEO and President of Bexion Pharmaceuticals, will [...]
Bexion Pharmaceuticals, Inc. to Present at the ESMO World Congress on Gastrointestinal Cancer 2023
COVINGTON, Ky., June 29, 2023– Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will be represented at the ESMO World Congress on Gastrointestinal Cancer 2023 taking place on June 28 – July 1, 2023, in Barcelona, Spain. Presentation Details: Title: BXQ-350: [...]
Bexion Pharmaceuticals, Inc. to Present at the 2023 American Association for Cancer Research (AACR) Annual Meeting and the International Ceramide Conference (ICC)
FOR IMMEDIATE RELEASE [Covington, KY--- April 18, 2023] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that the Company will be represented at two upcoming prestigious scientific conferences: American Association for Cancer Research Annual Meeting (AACR) April 14-19, 2023 Orlando, Florida Bexion [...]
Bexion Pharmaceuticals, Inc. to Present at the 22nd Annual Needham Virtual Healthcare Conference
FOR IMMEDIATE RELEASE [Covington, KY--- April 11, 2023] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that Bexion Pharmaceuticals will be presenting at the Needham Healthcare Conference. The conference will be held virtually from April 17-20, 2023. Scott Shively, Bexion’s CEO and President, [...]
Bexion Pharmaceuticals, Inc. Announces Publication of Pediatric Phase 1 (KOURAGE) Results
Study achieved planned maximum dose of BXQ-350 with strong safety profile FOR IMMEDIATE RELEASE Covington, KY, February 23, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today results from their clinical trial entitled, “An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent [...]
